Intro To Fda Advisory Committee Meetings: Aducanumab's Adcomm

Intro to FDA Advisory Committee meetings: aducanumab's AdComm

Analyzing FDA Ad Comm minutes: was the aducanumab Ad Comm biased?

June 10, 2024 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS)

U.S. Food and Drug Administration

June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC)

U.S. Food and Drug Administration

185th Meeting of Vaccines and Related Biological Products Advisory Committee

U.S. Food and Drug Administration

June 9, 2023 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS)

U.S. Food and Drug Administration

Public Meeting: Optimizing FDA’s Use of and Processes for Advisory Committees (Afternoon Portion)

U.S. Food and Drug Administration

Ask A Scientist: What is an FDA ADComm?

Spectrum Science

FDA Approval of Aducanumab for Alzheimer’s Disease

Case Western Reserve University School of Law

76th Cellular, Tissue, and Gene Therapies Advisory Committee

U.S. Food and Drug Administration

Oral Testimony to the FDA Advisory Committee on the Approval of AMX0035

Les Turner ALS Foundation

November 8, 2022 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC)

U.S. Food and Drug Administration

March 22, 2023 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS)

U.S. Food and Drug Administration

April 24 - The day before FDA Advisory Committee Meeting

Center for Duchenne Muscular Dystrophy UCLA

Formal Meetings for PDUFA Products and Communication Best Practices (4of14) REdI 2018

U.S. Food and Drug Administration

March 30, 2022 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee

U.S. Food and Drug Administration

What to Expect from the FDA Ad Comms [November 2015 Webinar]

Parent Project Muscular Dystrophy

Analyzing FDA's statistical review of a Phase 3 program

Oral Testimony by Dr. Senda Ajroud-Driss to the FDA Advisory Committee meeting on tofersen

Les Turner ALS Foundation

Preparing for the Nurown FDA Advisory Committee